TY - CHAP
T1 - The psychopharmacology of catatonia, neuroleptic malignant syndrome, akathisia, tardive dyskinesia, and dystonia
AU - Sienaert, Pascal
AU - van Harten, Peter
AU - Rhebergen, Didi
PY - 2019
Y1 - 2019
N2 - Although highly prevalent, motor syndromes in psychiatry and motor side effects of psychopharmacologic agents remain understudied. Catatonia is a syndrome with specific motor abnormalities that can be seen in the context of a variety of psychiatric and somatic conditions. The neuroleptic malignant syndrome is a lethal variant, induced by antipsychotic drugs. Therefore, antipsychotics should be used with caution in the presence of catatonic signs. Antipsychotics and other dopamine-antagonist drugs can also cause motor side effects such as akathisia, (tardive) dyskinesia, and dystonia. These syndromes share a debilitating impact on the functioning and well-being of patients. To reduce the risk of inducing these side effects, a balanced and well-advised prescription of antipsychotics is of utmost importance. Clinicians should be able to recognize motor side effects and be knowledgeable of the different treatment modalities.
AB - Although highly prevalent, motor syndromes in psychiatry and motor side effects of psychopharmacologic agents remain understudied. Catatonia is a syndrome with specific motor abnormalities that can be seen in the context of a variety of psychiatric and somatic conditions. The neuroleptic malignant syndrome is a lethal variant, induced by antipsychotic drugs. Therefore, antipsychotics should be used with caution in the presence of catatonic signs. Antipsychotics and other dopamine-antagonist drugs can also cause motor side effects such as akathisia, (tardive) dyskinesia, and dystonia. These syndromes share a debilitating impact on the functioning and well-being of patients. To reduce the risk of inducing these side effects, a balanced and well-advised prescription of antipsychotics is of utmost importance. Clinicians should be able to recognize motor side effects and be knowledgeable of the different treatment modalities.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85074672548&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31727227
U2 - https://doi.org/10.1016/B978-0-444-64012-3.00025-3
DO - https://doi.org/10.1016/B978-0-444-64012-3.00025-3
M3 - Chapter
C2 - 31727227
VL - 165
T3 - Handbook of Clinical Neurology
SP - 415
EP - 428
BT - Handbook of Clinical Neurology
PB - Elsevier B.V
ER -